Virax Biolabs
VRAX
7 hedge funds and large institutions have $990K invested in Virax Biolabs in 2022 Q4 according to their latest regulatory filings, with 6 funds opening new positions, increasing their positions, 1 reducing their positions, and 3 closing their positions.
441% more capital invested
Capital invested by funds: $183K → $990K (+$807K)
100% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 3
75% more funds holding
Funds holding: 4 → 7 (+3)
0.01% more ownership
Funds ownership: 0% → 0.01% (+0.01%)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KI
Kapitalo Investimentos
Sao Paulo,
Brazil
|
+$167K |
| 2 |
Legal & General Group
London,
United Kingdom
|
+$146K |
| 3 |
VF
Virtu Financial
New York
|
+$68.9K |
| 4 |
Millennium Management
New York
|
+$22K |
| 5 |
Renaissance Technologies
New York
|
+$16.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SSA
Schonfeld Strategic Advisors
New York
|
-$115K |
| 2 |
Bank of America
Charlotte,
North Carolina
|
-$28K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$8.53K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$2K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
KI
1
Kapitalo Investimentos
Sao Paulo,
Brazil
| $858K | +$167K | +470 | New |
|
|
2
Legal & General Group
London,
United Kingdom
| $73.5K | +$146K | +410 | New |
|
|
VF
3
Virtu Financial
New York
| $35K | +$68.9K | +194 | New |
|
|
4
Millennium Management
New York
| $11K | +$22K | +62 | New |
|
|
5
Renaissance Technologies
New York
| $8K | +$16.3K | +46 | New |
|
|
6
UBS Group
Zurich,
Switzerland
| $4.51K | -$8.53K | -24 | -49% |
|
7
Morgan Stanley
New York
| $623 | +$1.07K | +3 | New |
|
|
RAM
8
Riggs Asset Management
Dallas,
Pennsylvania
| $3 | – | – | – |
|
|
SSA
9
Schonfeld Strategic Advisors
New York
| – | -$115K | -146 | Closed |
|
|
10
Bank of America
Charlotte,
North Carolina
| – | -$28K | -36 | Closed |
|
|
TRCT
11
Tower Research Capital (TRC)
New York
| – | -$2K | -3 | Closed |
|
VRAX Hedge Fund Activity: Q4 2022 in Review
7 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Virax Biolabs (VRAX) for Q4 2022, worth a combined $990K — up 441% from $183K a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new VRAX positions and 3 closed out — a net gain of 3 holders — while 0 added to existing stakes and 1 trimmed.
The largest buyer was Kapitalo Investimentos, opening a new position worth an estimated $167K. The largest seller was Schonfeld Strategic Advisors, exiting entirely with an estimated $115K sold.
- 7 institutional investors held Virax Biolabs (VRAX) as of Q4 2022, up from 4 in Q3 2022.
- Funds reported $990K of Virax Biolabs stock for Q4 2022, up 441% quarter-over-quarter.
- 6 funds opened new Virax Biolabs positions in Q4 2022 and 3 closed out, a net change of +3 holders.
- The largest Virax Biolabs buyer in Q4 2022 was Kapitalo Investimentos, an estimated $167K added.
- The largest Virax Biolabs seller in Q4 2022 was Schonfeld Strategic Advisors, an estimated $115K sold.
Based on aggregated 13F filings for Q4 2022.